GT Biopharma, Inc. (GTBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 150K 300K 450K FY10: 11K FY11: 26K FY12: 342K FY13: 368K FY14: 61K FY15: 27K FY16: 0 FY17: 0 FY19: 0 FY20: 0 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY19 FY20

Gross Profit Annual

-90K 0 90K 180K 270K FY10: -54K FY11: -22K FY12: 248K FY13: 142K FY14: 4K FY15: 27K FY16: 0 FY17: 0 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17

Operating Income Annual

-270M -180M -90M 0 90M 180M 270M FY10: -2.5M FY11: -3.9M FY12: -3.5M FY13: -793K FY14: -2.4M FY15: -8.9M FY16: -9.4M FY17: -135.6M FY18: -250.1M FY19: 16.1M FY20: -6.8M FY21: -57.5M FY22: -21.3M FY23: -13.6M FY24: -14.4M FY25: -12.4M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-270M -180M -90M 0 90M 180M 270M FY10: -3M FY11: -3.7M FY12: -5.2M FY13: -501K FY14: -23.5M FY15: -21.5M FY16: 9.8M FY17: -144.2M FY18: -259.2M FY19: -38.6M FY20: -28.3M FY21: -58M FY22: -20.9M FY23: -7.6M FY24: -13.2M FY25: -28.4M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 80K 160K 240K FY10: 65K FY11: 48K FY12: 94K FY13: 226K FY14: 57K FY15: 0 FY16: 0 FY17: 0 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17

Operating Cash Flow Annual

-18M -12M -6M 0 6M 12M 18M FY10: -1.5M FY11: -963K FY12: -987K FY13: -442K FY14: -1.7M FY15: -4.7M FY16: -1.9M FY17: -5.4M FY18: -10.7M FY19: -3.7M FY20: -7.3M FY21: -15.6M FY22: -15.2M FY23: -8.9M FY24: -12.9M FY25: -12.9M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-12M -8M -4M 0 4M 8M 12M FY11: -963K FY12: -989K FY13: -442K FY14: -1.8M FY15: -4.7M FY16: -1.9M FY17: -5.4M FY18: -10.7M FY19: -3.7M FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 10M 20M 30M FY15: 2.4M FY16: 81.5K FY17: 16.8K FY18: 50.2K FY19: 3.4M FY20: 4.4M FY21: 28.2M FY22: 1.1M FY23: 1.3M FY24: 1.9M FY25: 5.5M FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-50.00 0.00 50.00 100.00 150.00 Q4 '10: -0.03 Q1 '11: -0.01 Q2 '11: -0.01 Q3 '11: -0.02 Q4 '11: -0.02 Q1 '12: -0.01 Q2 '12: -0.02 Q3 '12: -0.02 Q4 '12: -0.01 Q1 '13: -0.01 Q2 '13: 0.00 Q3 '13: 0.00 Q4 '13: -0.01 Q1 '14: -0.01 Q2 '14: -0.01 Q3 '14: -0.02 Q4 '14: -0.04 Q1 '15: -8.65 Q2 '15: -3.18 Q3 '15: -2.46 Q4 '15: -12.37 Q1 '16: -2.92 Q2 '16: -8.33 Q3 '16: -8.91 Q4 '16: 120.38 Q1 '17: 93.18 Q2 '19: -4.91 Q3 '19: -0.72 Q4 '20: -10.93 Q1 '21: -12.74 Q2 '21: -8.77 Q3 '21: -8.30 Q4 '21: -2.67 Q1 '22: -1.01 Q2 '22: -0.96 Q3 '22: -1.01 Q4 '22: -19.67 Q1 '23: -19.71 Q2 '23: -21.10 Q3 '23: -22.65 Q4 '23: -5.64 Q1 '24: -7.07 Q2 '24: -7.75 Q3 '24: -7.51 Q4 '24: -7.00 Q1 '25: -5.69 Q2 '25: -14.44 Q3 '25: -11.87 Q4 '25: -6.68 Q1 '26: -6.46 Q2 '26: 4.34 Q1 '11 Q4 '12 Q3 '14 Q2 '16 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.